Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Shares of Solventum are down 1.27% at $87.03. The company is worth $14.81B, number 684 out of 800 on our list.
Over a full year the shares have ranged across $62.38 to $94.16, which puts the current price roughly 78% of the way up that band. Holders are ahead 19.2% over twelve months, and up 11.1% across the last three months.
Price is below the 50-day average ($87.71) but above the 200-day ($77.89); RSI is 47, and the last 30 sessions moved at roughly 17% annualized volatility.
Revenue for the quarter ended Jun 2026 was $2.21B, up 2.2% from a year earlier, with $93.00M of net profit (a 17.3% margin).
Buyers are paying 10.6 times trailing earnings, 35% below its five-year average of 16.4. The median for its industry group is 30.7.
10 analysts follow the stock and the average call is "buy". The mean target, $98.20, sits 12.8% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
10 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
SOLV is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $98.20, 12.8% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $71.00, so shares trade 22.6% above that estimate. On earnings multiple, it sits in the 46th percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -2.6% | Bearish |
| Price vs 50-day average | -0.8% | Bearish |
| Price vs 200-day average | +11.7% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 47.2 | Bearish |
| MACD (12,26,9) | 0.23 | Bearish |
| Bollinger band position | 8% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 1, 2026 11:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 10.6x earnings, SOLV looks cheap against the market, and trades 65% below the 30.7x median among Medical Instruments & Supplies names. The two comparisons do not always agree.
$87.03 is the latest print for SOLV, a move of -1.27% against yesterday's close of $88.15. Today's low and high so far: $86.67 and $88.55.
Equity value comes to $14.81B at the current price. By that measure it is number 684 of the 800 names in our coverage.
Buyers pay 10.6 times the last twelve months of profit (EPS $8.88). Averaged over five years the multiple has been 16.4, and today's level ranks in the 46th percentile of its own history.
The year's floor is $62.38 and the ceiling $94.16. Shares are 7.6% away from that ceiling.
Our data shows no dividend paid by Solventum over the trailing twelve months.
Of 10 analysts, 70% say buy, 30% hold and 0% sell. Price targets average $98.20, with the most cautious at $81.00 and the most optimistic at $113.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on SOLV.